AbbVie Inc (NYSE:ABBV)

66.07
Delayed Data
As of Apr 24
 +1.82 / +2.83%
Today’s Change
48.95
Today|||52-Week Range
70.76
+0.96%
Year-to-Date
No end in sight to wave of pharma dealmaking
Apr 26 / FT.com
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Apr 21 / Zacks.com
Can You Guess Which State Won't Pay for Hepatitis C Drugs?
Apr 26 / MotleyFool.com
Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
Apr 21 / Zacks.com
Trusty Horses; Tools, Pizza and Shoes: Jim Cramer's Best Blogs
Apr 25 / TheStreet.com
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Apr 21 / Zacks.com
Are Biosimilars the Next Big Thing in Biotech?
Apr 25 / MotleyFool.com
AbbVie Refiles for Antitrust Review of Pharmacyclics Deal
Apr 20 / TheStreet.com
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog
Apr 24 / Zacks.com
Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent
Apr 20 / Benzinga
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog
Apr 24 / Zacks.com
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog
Apr 20 / Zacks.com
Until Next Time ...
Apr 24 / TheStreet.com
3 Stocks Pushing The Drugs Industry Higher
Apr 20 / TheStreet.com
Today's Top Performers In Drugs
Apr 24 / TheStreet.com
Double-Digit Spike in Drug Costs Prescribes Profits for PBMs
Apr 20 / MotleyFool.com
AbbVie (ABBV) Earnings Report: Q1 2015 Conference Call Transcript
Apr 24 / TheStreet.com
What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Apr 18 / MotleyFool.com
Gilead (GILD) Announces Encouraging Data on its HCV Drugs - Analyst Blog
Apr 23 / Zacks.com
AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
Apr 16 / Zacks.com
AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog
Apr 23 / Zacks.com
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
Apr 16 / MotleyFool.com
Humira Propels AbbVie Inc. to a Solid First Quarter
Apr 23 / MotleyFool.com
Healthcare ETFs in Focus Post JNJ Earnings Beat - ETF News And Commentary
Apr 16 / Zacks.com
Arris Group to Acquire U.K.'s Pace to Expand, Save on Taxes
Apr 23 / TheStreet.com
The Best Stock to Invest in Hep C
Apr 16 / MotleyFool.com
Arris Group to Acquire U.K.'s Pace to Expand, Save on Taxes
Apr 23 / TheStreet.com
Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog
Apr 15 / Zacks.com
AbbVie Beats Q1 Views, Raises Earnings Outlook
Apr 23 / Benzinga
3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog
Apr 15 / Zacks.com
Water-Logged And Getting Wetter: AbbVie (ABBV)
Apr 23 / TheStreet.com
3 Promising Healthcare Stocks Under $10
Apr 15 / MotleyFool.com
AbbVie (ABBV) Tops 1Q Earnings and Revenue Estimates - Tale of the Tape
Apr 23 / Zacks.com
J&J cuts guidance as strong dollar hits sales
Apr 14 / FT.com
5 Things UnitedHealth Wants You to Know
Apr 23 / MotleyFool.com
Biotech: Making sense of the science
Apr 13 / FT.com
Earnings Scheduled For April 23, 2015
Apr 23 / Benzinga
Gilead combats wider distribution of cheap drugs from EM
Apr 12 / FT.com
Pace $2.1bn takeover extends tax inversion deals
Apr 22 / FT.com
Biosimilar drugs: spot the difference
Apr 08 / FT.com
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampi...
Apr 22 / Zacks.com
Healthcare sector leads feverish M&A activity
Mar 30 / FT.com
Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog
Apr 21 / Zacks.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account